Brainsway Ltd
BWAY15.590USD
0.000
Handelsschluss 11/07, 16:00（ET）Kurse um 15 Minuten verzögert
589.14MMarktkapitalisierung
110.24KGV TTM
mehr Informationen über Brainsway Ltd Unternehmen
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
Brainsway Ltd Informationen
BörsenkürzelBWAY
Name des UnternehmensBrainsway Ltd
IPO-datumDec 24, 2006
CEOMr. Hadar Levy
Anzahl der mitarbeiter120
WertpapierartOrdinary Share
GeschäftsjahresendeDec 24
Addresse16 Hartum Street Rad Tower, 14Th Floor
StadtJERUSALEM
BörseTel Aviv Stock Exchange
LandIsrael
Postleitzahl9777516
Telefon97225813140
Websitehttps://www.brainsway.com/
BörsenkürzelBWAY
IPO-datumDec 24, 2006
CEOMr. Hadar Levy
Führungskräfte von Brainsway Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Colleen A. Hanlon, Ph.D.
Dr. Colleen A. Hanlon, Ph.D.
Vice President - Medical Affairs
Vice President - Medical Affairs
--
--
Mr. Avner Lushi
Mr. Avner Lushi
Independent Director
Independent Director
--
--
Dr. David Zacut, M.D.
Dr. David Zacut, M.D.
Vice Chairman of the Board
Vice Chairman of the Board
--
--
Mr. Avner Hagai
Mr. Avner Hagai
Independent Director
Independent Director
--
--
Prof. Abraham Zangen, Ph.D.
Prof. Abraham Zangen, Ph.D.
Director
Director
--
--
Mr. Ido Marom
Mr. Ido Marom
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Amiram (Ami) Boehm
Mr. Amiram (Ami) Boehm
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Hadar Levy
Mr. Hadar Levy
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Karen Sarid
Ms. Karen Sarid
Independent Director
Independent Director
--
--
Ms. Eti Michal Mitrany Rayten
Ms. Eti Michal Mitrany Rayten
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Colleen A. Hanlon, Ph.D.
Dr. Colleen A. Hanlon, Ph.D.
Vice President - Medical Affairs
Vice President - Medical Affairs
--
--
Mr. Avner Lushi
Mr. Avner Lushi
Independent Director
Independent Director
--
--
Dr. David Zacut, M.D.
Dr. David Zacut, M.D.
Vice Chairman of the Board
Vice Chairman of the Board
--
--
Mr. Avner Hagai
Mr. Avner Hagai
Independent Director
Independent Director
--
--
Prof. Abraham Zangen, Ph.D.
Prof. Abraham Zangen, Ph.D.
Director
Director
--
--
Mr. Ido Marom
Mr. Ido Marom
Chief Financial Officer
Chief Financial Officer
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
33.23M
81.01%
Other
7.79M
18.99%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Valor Equity Partners
13.59%
Masters Capital Management, L.L.C.
5.11%
Phoenix Financial Ltd
3.56%
Acadian Asset Management LLC
1.71%
Essex Investment Management Company, LLC
1.59%
Andere
74.44%
Aktionäre
Aktionäre
Anteil
Valor Equity Partners
13.59%
Masters Capital Management, L.L.C.
5.11%
Phoenix Financial Ltd
3.56%
Acadian Asset Management LLC
1.71%
Essex Investment Management Company, LLC
1.59%
Andere
74.44%
Aktionärstypen
Aktionäre
Anteil
Private Equity
13.98%
Hedge Fund
9.39%
Investment Advisor/Hedge Fund
4.73%
Holding Company
3.67%
Investment Advisor
3.47%
Individual Investor
2.69%
Pension Fund
0.45%
Research Firm
0.31%
Andere
61.30%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
83
5.59M
28.96%
-873.84K
2025Q2
82
7.33M
38.85%
+597.38K
2025Q1
84
7.36M
38.96%
-890.13K
2024Q4
77
7.26M
38.54%
-2.72M
2024Q3
65
3.62M
21.68%
-5.03M
2024Q2
59
4.49M
26.92%
-3.10M
2024Q1
56
4.64M
27.89%
-3.35M
2023Q4
48
4.90M
29.50%
-2.87M
2023Q3
43
4.53M
27.32%
-3.32M
2023Q2
45
4.62M
27.86%
-2.51M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Valor Equity Partners
2.10M
11.07%
--
--
Jun 30, 2025
Masters Capital Management, L.L.C.
1.00M
5.26%
--
--
Jun 30, 2025
Phoenix Financial Ltd
697.26K
3.67%
+456.90K
+190.09%
Oct 18, 2024
Acadian Asset Management LLC
334.27K
1.76%
-2.31K
-0.69%
Jun 30, 2025
Essex Investment Management Company, LLC
300.94K
1.58%
-2.23K
-0.73%
Jun 30, 2025
Renaissance Technologies LLC
283.86K
1.49%
-14.40K
-4.83%
Jun 30, 2025
Shulkin (Jonathan K.)
268.25K
1.41%
+268.25K
--
Nov 05, 2024
Gracias (Antonio J)
243.50K
1.28%
+243.50K
--
Nov 05, 2024
ARK Investment Management LLC
199.83K
1.05%
+11.50K
+6.11%
Jun 30, 2025
Two Sigma Investments, LP
172.60K
0.91%
+1.82K
+1.07%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
ActivePassive International Equity ETF
0.04%
ARK Israel Innovative Technology ETF
0%
iShares Neuroscience and Healthcare ETF
0%
ActivePassive International Equity ETF
Anteil0.04%
ARK Israel Innovative Technology ETF
Anteil0%
iShares Neuroscience and Healthcare ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
